ALMS_OUT_1 [2025-03-26 14:23:02 -0400] 2018 Bytes | 587 tokens | Cum: 587 tkns (7.34% of 8k)
==========================================================================

We need a winner today and it's already 2:23:00 PM on Wed Mar 26, 2025 -0400 ... So let's find out if Alumis (ALMS) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 5.37 up from 4. Is there something here we can get excited about? Help me analyze.

Here's the first list of news for Alumis:

C1 - Mar-25-25 10:51AM - Alumis and Kaken sign agreement in Japan to develop ESK-001
C2 - Mar-25-25 10:51AM 02:30AM - Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
C3 - Mar-21-25 07:08AM - Why Alumis Inc. (ALMS) Went Down On Thursday?
C4 - Mar-19-25 04:05PM - Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
C5 - Mar-10-25 08:00AM - Alumis to Present at Leerink's 2025 Global Healthcare Conference
C6 - Mar-08-25 09:00AM - Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
C7 - Mar-04-25 09:01AM - Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
C8 - Mar-04-25 09:01AM 09:01AM - ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Alumis (ALMS)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ALMS_OUT_3 [2025-03-26 14:23:05 -0400] 1049 Bytes | 299 tokens | Cum: 888 tkns (11.10% of 8k)
==========================================================================

Showing C4 (chunk 1 of 19): C4:
**Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements**
Date: Mar-19-25 04:05PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/19/3045800/0/en/Alumis-Reports-Year-End-2024-Financial-Results-and-Highlights-Recent-Achievements.html

March 19, 2025 16:05 ET| Source:Alumis Inc.Alumis Inc.

– Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; Phase 3 ONWARD program data readout now expected 1Q 2026 –

– Presented Phase 1 clinical data at ACTRIMS 2025 demonstrating first-in-class oral TYK2 inhibitor A-005 has ability to cross blood-brain barrier and was well tolerated; Phase 2 in MS to begin 2H 2025 –

– Announced merger agreement with ACELYRIN to create combined company with differ

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ALMS_OUT_5 [2025-03-26 14:23:07 -0400] 1047 Bytes | 241 tokens | Cum: 1131 tkns (14.14% of 8k)
==========================================================================

Showing C4 (chunk 2 of 19): entiated late-stage portfolio of therapies and strong balance sheet; expected to close 2Q 2025 –

SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the year ended December 31, 2024, and highlighted recent achievements and upcoming milestones.

“Alumis concluded a strong 2024, continuing to establish our late-stage pipeline of next-generation oral TYK2 inhibitors that have the potential to address significant unmet patient needs in immune-mediated diseases around the world,” said Martin Babler, President and Chief Executive Officer of Alumis. “The next 12-18 months will bring major milestones for Alumis, wit

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ALMS_OUT_7 [2025-03-26 14:23:08 -0400] 1049 Bytes | 239 tokens | Cum: 1372 tkns (17.15% of 8k)
==========================================================================

Showing C4 (chunk 3 of 19): h topline data from the pivotal Phase 3 program for ESK-001 in moderate-to-severe plaque psoriasis expected in the first quarter of 2026. We also plan to initiate a Phase 2 trial of A-005 in multiple sclerosis in the second half of 2025 and expect data from ESK-001’s Phase 2b clinical trial in systemic lupus erythematosus in 2026. Together, these milestones underscore the importance of this time period as transformative in Alumis’ long-term growth strategy.”

Babler added “The announcement of the merger agreement with ACELYRIN represents a significant step forward in Alumis' strategic progress that will create a leading immunology and inflammation company with multiple upcoming expected development milestones and extend our runway into 2027. We look forward to the anticipated close of the transaction in the second quarter.”

About AlumisAlumis is a clinical-stage biopharmaceutical compan

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ALMS_OUT_9 [2025-03-26 14:23:10 -0400] 845 Bytes | 261 tokens | Cum: 1635 tkns (20.44% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-26T11:29:10Z - Q1 Earnings Estimate for Alumis Issued By Leerink Partnrs...
A2 - 2025-03-25T15:54:20Z - What's Going On With Alumis Shares Tuesday? - Alumis (NASDAQ:ALMS)...
A3 - 2025-03-25T12:50:06Z - Alumis stock soars on Japan dermatology deal By Investing.com...
A4 - 2025-03-25T12:48:00Z - Alumis stock soars on Japan dermatology deal By Investing.com...
A5 - 2025-03-25T12:50:06Z - Alumis stock soars on Japan dermatology deal By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ALMS_OUT_11 [2025-03-26 14:23:12 -0400] 1038 Bytes | 308 tokens | Cum: 1945 tkns (24.31% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Q1 Earnings Estimate for Alumis Issued By Leerink Partnrs**Date: 2025-03-26Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/q1-earnings-estimate-for-alumis-issued-by-leerink-partnrs-2025-03-25/Alumis Inc. (NASDAQ:ALMS - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Alumis in a research note issued on Sunday, March 23rd. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of ($1.46) for the quarter. The consensus estimate for Alumis' current full-year earnings is ($8.51) per share.

A number of other brokerages also recently weighed in on ALMS. HC Wainwright reiterated a "buy" rating and set a $15.00 price target (down from $19.00) on shares of Alumis in a report on Thursday, March 20th. Oppenheimer initiated coverage on Alumis i

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ALMS_OUT_13 [2025-03-26 14:23:13 -0400] 1038 Bytes | 276 tokens | Cum: 2223 tkns (27.79% of 8k)
==========================================================================

Showing A1 (chunk 2 of 5): n a report on Thursday, January 30th. They issued an "outperform" rating and a $32.00 target price for the company. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Alumis in a research note on Thursday, March 20th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $26.00.

View Our Latest Research Report on ALMS

NASDAQ:ALMS opened at $3.78 on Tuesday. Alumis has a 52 week low of $3.18 and a 52 week high of $13.53. The firm's fifty day moving average is $5.62 and its 200-day moving average is $8.49.

A number of large investors have recently modified their holdings of ALMS. Geode Capital Management LLC bought a new position in shares of Alumis in the third quarter valued at $3,266,000. State Street Corp acquir

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ALMS_OUT_15 [2025-03-26 14:23:15 -0400] 1096 Bytes | 341 tokens | Cum: 2566 tkns (32.07% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-19T20:05:00Z - Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
B2 - 2025-03-13T17:52:00Z - Metal-Organic Frameworks Market to Reach $949.2 Million by 2029, Growing at 15.6% CAGR
B3 - 2025-03-08T14:00:00Z - Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
B4 - 2025-03-04T14:01:00Z - Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
B5 - 2025-03-04T14:01:00Z - ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
B6 - 2025-02-06T21:15:00Z - Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ALMS_OUT_17 [2025-03-26 14:23:20 -0400] 699 Bytes | 171 tokens | Cum: 2739 tkns (34.24% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/25/03/g44405196/alumis-reports-year-end-2024-financial-results-and-highlights-recent-achievementsAlumis reported strong 2024 results, with progress on its late-stage pipeline of oral TYK2 inhibitors for immune-mediated diseases. The company also announced a merger agreement with ACELYRIN to create a combined company with a differentiated portfolio and increased financial flexibility.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ALMS_OUT_19 [2025-03-26 14:23:22 -0400] 1070 Bytes | 259 tokens | Cum: 3073 tkns (38.41% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-19 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our CONS financial statements and the related note...

S2 - 2025-03-19 8-K Item 2.02 Results of Oper and Fin Cond.

On March 19, 2025, Alumis Inc. (the Company) issued a press release announcing, among other things, its financial results for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99....

S3 - 2025-03-19 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our CONS financial statements and the related note...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ALMS_OUT_21 [2025-03-26 14:23:26 -0400] 943 Bytes | 235 tokens | Cum: 3310 tkns (41.38% of 8k)
==========================================================================

Showing S2 (chunk 1 of 1): S2:
Item 2.02 Results of Operations and Financial Condition.

On March 19, 2025, Alumis Inc. (the Company) issued a press release announcing, among other things, its financial results for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1.

All of the information furnished in this Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing....

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ALMS_OUT_23 [2025-03-26 14:23:39 -0400] 4798 Bytes | 1374 tokens | Cum: 4767 tkns (59.59% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+----------------------+------------------------+----------------------+-----------------------+
| Volume: 2,119,568 | SMA50: 1.21% | Market Cap: 306.05M | Option/Short: No / Yes | Sales past 5Y: 0.00% | Sales Surprise: - |
+---------------------+-----------------------+----------------------+------------------------+----------------------+-----------------------+
| Avg Volume: 425.76K | SMA200: -40.70% | Shs Outstand: 47.22M | Short Float: 12.08% | Employees: 168 | EPS Surprise: -24.94% |
+---------------------+-----------------------+----------------------+------------------------+----------------------+-----------------------+
| Rel Volume: 6.87 | Perf Week: 28.72% | Shs Float: 25.25M | Short Ratio: 7.16 | Debt/Eq: 0.12 | P/E: - |
+---------------------+-----------------------+----------------------+------------------------+----------------------+-----------------------+
| RSI (14): 60.05 | Perf Month: 15.98% | Inst Own: 34.73% | Short Interest: 3.05M | Sales Y/Y TTM: - | Earnings: Mar 19 AMC |
+---------------------+-----------------------+----------------------+------------------------+----------------------+-----------------------+
| ATR (14): 0.70 | Perf Quarter: -36.22% | Insider Own: 53.59% | Beta: - | ROE: -198.66% | |
+---------------------+-----------------------+----------------------+------------------------+----------------------+-----------------------+
| SMA20: 23.83% | Index: RUT | Insider Trans: 0.00% | Sales Q/Q: - | ROI: -101.72% | |
+---------------------+-----------------------+----------------------+------------------------+----------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: ALUMIS INC. (ALMS) by Babler Martin (President, CEO and Chairman) on 2025-02-18
- Stock Option (Right to Buy): 523000 shares at $0 (D)

Inside Trans: ALUMIS INC. (ALMS) by Goldstein David M (Chief Scientific Officer) on 2025-02-18
- Stock Option (Right to Buy): 180000 shares at $0 (D)

Inside Trans: ALUMIS INC. (ALMS) by Drappa Jorn (Chief Medical Officer) on 2025-02-18
- Stock Option (Right to Buy): 180000 shares at $0 (D)

Inside Trans: ALUMIS INC. (ALMS) by Klein Sara (Chief Legal Officer) on 2025-02-18
- Stock Option (Right to Buy): 180000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -294233000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 5.29
Average Volume: 905954.48
30-Day High: 5.29
30-Day Low: 3.57

[Detailed Financials: TTM 2024]
- Total Assets: $340,992,000.0
- Total Liabilities: $80,888,000.0
- Total Equity: $260,104,000.0
- Current Assets: $306,188,000.0
- Current Liabilities: $50,910,000.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -10.38

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $123,499,000.0

[Detailed Financials: FY 2024]
- Total Assets: $340,992,000.0
- Total Liabilities: $80,888,000.0
- Total Equity: $260,104,000.0
- Current Assets: $306,188,000.0
- Current Liabilities: $50,910,000.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -10.38

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $123,499,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

ALMS_OUT_25 [2025-03-26 14:23:42 -0400] 676 Bytes | 167 tokens | Cum: 5181 tkns (64.76% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ALMS_IN_27 [2025-03-26 14:23:42 -0400] 126 Bytes | 29 tokens | Cum: 5238 tkns (65.48% of 8k)
==========================================================================

====================================
[2025-03-26 11:23:42] # Analysis Completed
Elapsed Time: 42.51 seconds